Dennie Tempel - Publications

Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.

Journal: Cancers

Published: May 06, 2022

Oncostatin M: Risks and Benefits of a Novel Therapeutic Target for Atherosclerosis.

Journal: Current drug targets

Published: March 28, 2022

Bridging a diagnostic Kawasaki disease classifier from a microarray platform to a qRT-PCR assay.

Journal: Pediatric research

Published: February 03, 2022

Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: September 30, 2021

Common Variants Associated With OSMR Expression Contribute to Carotid Plaque Vulnerability, but Not to Cardiovascular Disease in Humans.

Journal: Frontiers in cardiovascular medicine

Published: January 26, 2021

Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.

Journal: International journal of dermatology

Published: December 22, 2020

Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

Journal: The British journal of dermatology

Published: August 18, 2020

Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.

Journal: International journal of dermatology

Published: March 03, 2020

Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans.

Journal: PloS one

Published: March 12, 2019

Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice.

Journal: PloS one

Published: May 25, 2018

Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis.

Journal: Molecular therapy. Methods & clinical development

Published: April 10, 2018

Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.

Journal: Neuro-oncology

Published: April 29, 2017